Sumário da prevenção da trombose venosa profunda na artroplastia total do joelho
DOI:
https://doi.org/10.23925/1984-4840.2018v20i1a2Palavras-chave:
próteses e implantes, artroplastia do joelho, trombose venosa, procedimentos cirúrgicos eletivos, complicações pós-operatórias.Resumo
Os autores descrevem uma atualização sucinta dos principais métodos de prevenção da trombose venosa profunda depois da artroplastia total do joelho, divididos em mecânicos e farmacológicos. Relatam as principais drogas utilizadas, sua dosagem, riscos e benefícios comparativos.
Downloads
Metrics
Referências
White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158(14):1525-31.
Barrack RL. Current guidelines for total joint VTE prophylaxis: dawn of a new day. J Bone Joint Surg Br. 2012;94(11 Suppl A):3-7. DOI: 10.1302/0301-620X.94B11.30824
Parvizi J, Jacovides CL, Bican O, Purtill JJ, Sharkey PF, Hozack WJ, et al. Is deep vein thrombosis a good proxy for pulmonary embolus? J Arthroplasty. 2010; 25(6 Suppl):138-44. DOI: 10.1016/j.arth.2010.05.001
Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):746-7. DOI: 10.2106/JBJS.9408.ebo746
Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25(7):1053-60. DOI: 10.1016/j.arth.2009.06.021
Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW. Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. J Arthroplasty. 2008;23(6 Suppl 1):20-4. DOI: 10.1016/j.arth.2008.05.018
Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006;452:175-80. DOI: 10.1097/01.blo.0000238822.78895.95
Parvizi J, Huang R, Restrepo C, Chen AF, Austin MS, Hozack WJ, et al. Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty: a preliminary analysis. J Bone Joint Surg Am. 2017;99(2):91-8. DOI: 10.2106/JBJS.16.00147
Liu F, Chu X, Huang J, Tian K, Hua J, Tong P. Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention. Arch Orthop Trauma Surg. 2014;134(5):679-83. DOI: 10.1007/s00402-014-1939-2
Arsoy D, Giori N, Woolson S. Mechanical compression reduces readmissions and wound complications from low molecular weight heparin after total hip or knee arthroplasty. In: AAOS 2017 Annual Meeting. San Diego: American Academy of Orthopaedic Surgeons; 2017.
Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345(18):1305-10. DOI: 10.1056/NEJMoa011099
Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-86. DOI: 10.1056/NEJMoa076016
Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, et al. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014;26(10):157-67. DOI: 10.2147/VHRM.S54714.eCollection 2014
Bloch BV, Patel V, Best AJ. Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement. Bone Joint J. 2014;96-B(1):122-6. DOI: 10.1302/0301-620X.96B1.31569
Yoshida RA, Yoshida WB, Rollo HA. Novos anticoagulantes orais para a profilaxia e tratamento do tromboembolismo venoso em cirurgias ortopédicas de grande porte. J Vasc Bras. 2011;10(2):145-53. DOI: http://dx.doi.org/10.1590/S1677-54492011000200009
Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012;94(2):257-64. DOI: 10.1302/0301-620X.94B2.27850
Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675. DOI: 10.1136/bmj.e3675
Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Postgrad Med. 2013;125(4):141-53. DOI: 10.3810/pgm.2013.07.2686.
Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, et al. Edoxaban versus enoxaparin for thrombophylaxis after total knee arthoplasty: the STARS E-3 trial. Thromb Res. 2014;134(6):1198-204. DOI: 10.1186/s12959-016-0121-1
Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, et al.; EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101(1):68-76.
Li J, Halaszynski T. Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions. Local Reg Anesth. 2015;8:21-32. DOI: 10.2147/LRA.S55306.eCollection 2015
Parvizi J, Hozack WJ, Arnold WV, Huang R, Raphael I, Rothman RH. Pulmonary embolism following total joint arthroplasty: when do they occur? In: AAOS 2012 Annual Meeting. Chicago: American Academy or Orthopaedic Surgeons; 2012.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Os autores no momento da submissão transferem os direitos autorais, assim, os manuscritos publicados passam a ser propriedade da revista.
O conteúdo do periódico está licenciado sob uma Licença Creative Commons 4.0, esta licença permite o livre acesso imediato ao trabalho e que qualquer usuário leia, baixe, copie, distribua, imprima, pesquise ou vincule aos textos completos dos artigos, rastreando-os para indexação, passá-los como dados para o software, ou usá-los para qualquer outra finalidade legal.